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Abstract While high risk of failure is an inherent part of developing innovative therapies, it can
be reduced by adherence to evidence-based rigorous research practices. Supported through the
European Union’s Innovative Medicines Initiative, the EQIPD consortium has developed a novel
preclinical research quality system that can be applied in both public and private sectors and is free
for anyone to use. The EQIPD Quality System was designed to be suited to boost innovation by
ensuring the generation of robust and reliable preclinical data while being lean, effective and not
becoming a burden that could negatively impact the freedom to explore scientific questions.
EQIPD defines research quality as the extent to which research data are fit for their intended use.
Fitness, in this context, is defined by the stakeholders, who are the scientists directly involved in
the research, but also their funders, sponsors, publishers, research tool manufacturers, and
collaboration partners such as peers in a multi-site research project. The essence of the EQIPD
Quality System is the set of 18 core requirements that can be addressed flexibly, according to user-
specific needs and following a user-defined trajectory. The EQIPD Quality System proposes
guidance on expectations for quality-related measures, defines criteria for adequate processes (i.e.
performance standards) and provides examples of how such measures can be developed and
implemented. However, it does not prescribe any pre-determined solutions. EQIPD has also
developed tools (for optional use) to support users in implementing the system and assessment
services for those research units that successfully implement the quality system and seek formal
accreditation. Building upon the feedback from users and continuous improvement, a sustainable
EQIPD Quality System will ultimately serve the entire community of scientists conducting non-
regulated preclinical research, by helping them generate reliable data that are fit for their intended
use.
The challenge: discovery of novel therapies requires rigor in
research practices
The success rate in the discovery of novel, safe and effective pharmacotherapies has been declining
steadily over the last few decades (Scannell et al., 2012). There are several factors likely accounting
for this unfortunate record (DiMasi et al., 2016; Waring et al., 2015; Shih et al., 2018). While some
of these factors (e.g. deeper knowledge of disease biology or clinical trial methodology) will take
years, if not decades, of continued research to be properly addressed, others can be readily con-
trolled today (Bespalov et al., 2016; Landis et al., 2012). One area requiring immediate attention is
research rigor, which is estimated to be lacking in 50–90% of preclinical studies (Freedman et al.,
2015).
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High risk of failure is an inherent part of developing innovative therapies (DiMasi et al., 2016).
However, some risks can be greatly reduced and avoided by adherence to evidence-based rigorous
research practices. Indeed, numerous analyses conducted to date have clearly identified measures
that need to be taken to improve research rigor (Begley and Ioannidis, 2015; Landis et al., 2012;
Ritskes-Hoitinga and Wever, 2018; Vollert et al., 2020; Volsen and Masson, 2009).
The EQIPD consortium: enhancing research quality as the
main objective
Improving research rigor has biomedical, societal, personal, economic and ethical benefits for acade-
mia and industry alike, since the development of novel therapies is often rooted in academic discov-
eries and requires a highly specialized effort of industry to translate these discoveries into clinically
useful applications. Moreover, the simple dichotomy between purely academic research and large
industry/big pharma efforts is currently being replaced by networks of biotechs, spin-offs, private
and public funders, contract research organizations (CROs), academic institutions engaging in drug
discovery projects and manufacturers of research tools. It is therefore important that strategies to
increase the robustness and reliability of preclinical research, both in terms of conduct and reporting,
involve all these different stakeholders.
To address this challenge in preclinical biomedical research in a collaborative manner, the
Enhancing Quality in Preclinical Data (EQIPD; originally called European Quality in Preclinical Data)
consortium was formed in 2017 with founding members from 29 institutions across eight different
countries (https://quality-preclinical-data.eu). The consortium works closely with a large group of
associated collaborators, advisors and stakeholders representing research institutions, publishers,
funders, learned societies and professional societies, from more than 100 organizations in Europe
and the US.
Supported through the European Union’s Innovative Medicines Initiative (IMI), the EQIPD consor-
tium, among other deliverables, aimed to develop a novel preclinical research quality system that
can be applied in both the public and private sectors. Such a quality system should be suited to
boost innovation by ensuring the generation of robust and reliable preclinical data while being lean,
effective and not becoming a burden that could negatively impact the freedom to explore scientific
questions.
EQIPD defines research quality as the extent to which research data are fit for intended use (for
related definitions and explanations, see Juran and Godfrey, 1999; Gilis, 2020). Fitness, in this con-
text, is defined by the stakeholders, who can be scientists themselves, but also patients, funders,
sponsors, publishers, and collaboration partners (e.g. peers in a multi-site research project).
The EQIPD consortium has developed a quality system that is free for anyone to use. Further,
EQIPD is preparing training, support and assessment services for those research units that success-
fully implement the quality system and would like to seek formal accreditation.
A new quality system to boost innovation
Quality systems usually appear as a response to an existing need (Table 1). For example, the devel-
opment of the Good Laboratory Practice (GLP) standards, introduced first by the Food and Drug
Administration (FDA) in the late 1970s, was triggered by poor research practices that compromised
human health, such as mis-identification of control and experimental animals, omitted, non-reported
or suppressed scientific findings, data inventions, replacements of animals lost to follow-up, and mis-
dosing of animals (Bongiovanni et al., 2020; Marshall, 1983). In the Organisation for Economic Co-
operation and Development (OECD) Principles (https://www.oecd.org/chemicalsafety/testing/over-
view-of-good-laboratory-practice.htm), GLP is defined as ’a quality system concerned with the
organisational process and the conditions under which non-clinical health and environmental safety
studies are planned, performed, monitored, recorded, archived and reported’.
GLP is a standard approach to quality in the regulated areas of preclinical drug development
(which largely relate to non-clinical safety and toxicology studies rather than efficacy; see Appendix
1 Glossary for a definition of regulated research), where trained personnel perform mainly routine
analyses, following defined Standard Operating Procedures (SOPs), and deliver data ultimately sup-
porting patient safety.
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There have been attempts to develop a quality system based on GLP, that is, taking GLP as the
basis and eliminating elements that are seen as excessive for the purposes of non-regulated drug
discovery. However, GLP does not provide explicit guidance regarding those aspects of study
design, conduct, analysis and reporting that are important to minimize the risk of bias and make
research robust. In other words, even if it were made less demanding, conventional GLP cannot
address some of today’s key challenges in non-regulated preclinical research.
In contrast, the EQIPD Quality System is a novel system specifically aimed at supporting innova-
tion in preclinical biomedical research. While the direct consequence of installing a quality system
will be the generation of research data that are of higher rigor, the ultimate goal is to improve the
efficiency of developing novel effective and safe therapies.
Development of a new quality system by EQIPD
EQIPD was started in October 2017 and during the first phase (until June 2018), three work pack-
ages of the EQIPD consortium have delivered:
. A systematic review of guidelines for internal validity in the design, conduct and analysis of
research involving laboratory animals (Vollert et al., 2020);
. An inventory of current practices and expectations toward quality management in non-regu-
lated preclinical research (based on interviews with 70 consortium members and stakeholders);
Table 1. Comparison of quality systems.
Quality system ISO 9001
GLP
(FDA, OECD) EQIPD
Year Launched 1987, 2015 1976, 1981 2020
Application area A general QMS that can be applied to all
aspects of organizations (not focused on
biomedical research)
Non-clinical health and environmental






Procuring organizations needed a basis of
contractual arrangements with their
suppliers (i.e., basic requirements for a
supplier to assure product quality)
Regulators such as FDA aimed to avoid
poorly managed or fraudulent non-clinical
studies on safety of new drugs
Biomedical research community (industry
and academia) recognized the negative
impact of lacking research rigor on the
development of novel therapeutics, and the
need for a comprehensive practical solution
to help enhance preclinical data reliability
Customers Typically outside of the organization
(anyone who requires a product or service)
Typically outside of the organization
(patients, regulators, sponsors, etc.)
In most cases, both inside (scientists
themselves) and outside (patients, funders,
collaboration partners, publishers, etc.) of
the organization
Objectives To certify that a product (which can be
preclinical data) or a service is provided with
consistent, good-quality characteristics,
which satisfy the stated or implied needs of
customers
To ensure the quality, integrity and
reliability of data on the properties and/or
safety of test items concerning human
health and/or the environment
To facilitate generating robust and reliable
preclinical data and thereby boost
innovation
Main focus Standardization of processes
The organizational overall performance is
continuously improved (process approach)
to enhance customer satisfaction and
development initiatives are done on a
sound basis for sustainability
The organizational process and the
conditions under which non-clinical health
and environmental safety studies are
planned, performed, monitored, recorded,
archived and reported
The outcome of research activities that is
robust, reliable, traceable, properly
recorded, reconstructible, securely stored






(advisable for larger organizations)
Required Not required





Not required Required Advisable, but not required
Assessments External (ISO auditors) and internal (internal
auditors)
External (health authorities/governmental
inspectors) and internal (QA auditors)
Self-assessment (by Process Owner),
external (by EQIPD)*
*Additional internal assessments may be conducted by qualified colleagues (e.g. dedicated quality professionals) outside the research unit but within the
same organization (advisable for larger organizations).
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. A review and analysis of governance in existing quality management systems (AAALAC Inter-
national; ASQ Best Quality Practices for Biomedical Research in Drug Development; BBSRC
Joint Code of Practice; ISO 9001, ISO 17025, ISO 15189; Janssen discovery quality system;
Novartis research quality system; OECD Principles of GLP; RQA – Quality Systems Workbook).
During the second phase (July 2018 - January 2019), a working group was assembled from the
EQIPD consortium members (n = 20). Based on the collected information, the working group nomi-
nated 75 statements that could define a functional quality system in non-regulated research. After
three Delphi feedback rounds and two consensus meetings, these statements were revised, resulting
in a final list of 18 core requirements (Table 2; see below for details).
During the third phase (February 2019 – September 2019), a supporting framework was devel-
oped (see below) and pilot implementation of the quality system started at four independent
research sites.
Based on the feedback from those pilot implementation sites and interactions with the stake-
holder group, an updated version of the framework was released for beta-testing in November
2019. The final version of the quality system was released in September 2020.
The EQIPD Quality System: key features
Table 3 presents five principles on which the EQIPD Quality System is based. These principles delin-
eate in a maximally concise and direct form that the EQIPD Quality System is meant to support sci-
entists in triggering changes in research practices, and that it will help to identify objectives and
direction of change but will not prescribe any specific solutions as long as the research processes are
kept transparent and traceable.
The EQIPD Quality System will deal with highly diverse research environments and associated
challenges. The five principles are, therefore, instrumental in finding answers to specific questions –
for example, is this particular practice in line with the EQIPD expectations? or should this particular
process be documented?
Table 2. EQIPD Core Requirements.
Categories # Item
Research team 1 Process Owner for the EQIPD Quality System must be identified
2 Communication process must be in place
Quality culture 3 The research unit must have defined quality objectives
4 All activities must comply with relevant legislation and policies
5 The research unit must have a procedure to act upon concerns of potential misconduct
Data integrity 6 Generation, handling and changes to data records must be documented
7 Data storage must be secured at least for as long as required by legal, contractual or other obligations or business needs
8 Reported research outcomes must be traceable to experimental data
9 Reported data must disclose all repetitions of a study, an experiment, or a test regardless of the outcome
Research processes 10 Investigator must declare in advance whether a study is intended to inform a formal knowledge claim
11 All personnel involved in research must have adequate training and competence to perform assigned tasks
12 Protocols for experimental methods must be available
13 Adequate handling and storage of samples and materials must be ensured
14 Research equipment and tools must be suitable for intended use and ensure data integrity
Continuous
improvement
15 Risk assessment must be performed to identify factors affecting the generation, processing and reporting of research data
16 Critical incidents and errors during study conduct must be analyzed and appropriately managed
17 An approach must be in place to monitor the performance of the EQIPD Quality System, and address identified issues
Sustainability 18 Resources for sustaining the EQIPD Quality System must be available
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Flexible: driven by the needs of an individual research unit
Research environments are highly diverse: the needs of researchers at a big pharma company are
different from those at a biotech; the needs of CROs are different from those of academic labs, etc.
Thus, improving data quality is a challenge that cannot be tackled using a one-size-fits-all solution
and flexibility is a critical requirement for future success.
The EQIPD Quality System is flexible: researchers are not confronted with a long and definitive
A-to-Z list of what should be done and in what sequence. Instead, implementation of the EQIPD
Quality System is characterized by:
. user-specific content – that is the exact nature of the individual elements of the EQIPD Quality
System are defined largely by the users and their environment;
. a variable trajectory – that is there are very limited expectations regarding the sequence of
introducing the different elements of the EQIPD Quality System; and
. no deadlines or fixed timelines – that is each unit adopts the EQIPD Quality System at its own
pace, depending on the existing needs and available resources.
EQIPD has developed tools (for optional use) that help scientists to identify and organize informa-
tion to address their own customized needs (e.g. related to my research funding source, my national
regulations for the use of animals, expectations of my collaboration partners, policies set by my insti-
tution, my own commitment to research rigor, etc.). Being unique to a research unit or a researcher,
such needs can be very specific to local or personal circumstances (i.e. essential for my success, my
funding, my career, for instance because of the requirements of my preferred funder), and as such
may be addressed with a higher or lower priority. Based on these factors, each research unit or
researcher can determine their sequence of actions (Figure 1). EQIPD tools offer examples and
ready-to-use solutions as well as information to develop new user-specific solutions.
For example, EQIPD has reviewed research quality expectations of several major public funders
and pharmaceutical companies. Summaries of these expectations as well as examples of how these
expectations can be met are available for downloading from the EQIPD’s online Toolbox (https://
eqipd-toolbox.paasp.net).
Table 3. Key principles.
Principle Explanation
Examples




Decisions about specific needs and solutions are made by
researchers, and not by EQIPD. EQIPD has formulated core
requirements for the QS implementation and, as a partner in this
process, EQIPD asks critical questions and provides
recommendations that are voluntary to follow and are provided only
to help the researchers throughout the implementation and use.
EQIPD recommends applying randomization to all studies but it is for
the researcher to decide whether randomization is applied to a




What it means to have the right quality level in place is suggested by
your environment (collaborators, funders, institution, etc.). EQIPD
does not ‘invent’ needs or requirements of your funders or your
collaborators. As a partner in this process, EQIPD QS only allows you
to see these requirements better and suggests ways of implementing
them (Gilis, 2020).
EQIPD identifies overlapping requirements from different
stakeholders toward the use and reporting of randomization.
Focus on
goal
Focus on the outcome (performance standards), not on the path,
timelines or the tools to get there (Guillén, 2010).
EQIPD highlights the importance of ‘randomness’ (lack of pattern or
predictability) in the correctly developed randomization sequence
but leaves it up to the user to select a specific method or tool.
Be
transparent
Key research processes must be transparent. This principle applies
specifically to retention and accessibility of information related to key
decisions related to study design, conduct, or analysis (e.g. decisions
to include or exclude certain data points in the analysis).
If one decides not to apply randomization, the decision must be
stated and must be justified, recorded and reported.
Leave a
trace
Key research processes must be traceable. Complementary to the
principle above, this principle refers to retention and accessibility of
all information that is necessary for a complete reconstruction of a key
research process (e.g. raw data related to reported data are findable,
and reported data are reconstructable from raw data).
If one does apply randomization, the way you apply randomization
must be traceable and reported.
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Team effort: understanding and endorsing research quality objectives
The focus on the specific needs of an individual research unit is ensured by the Process Owner, a
person within the organization who has access to the necessary resources, and the competence and
the authority to implement all steps needed to establish the EQIPD Quality System. Typically, the
Process Owner should be someone who directs the work of the research unit (e.g. group leader,
principal investigator, CEO or department head) and is knowledgeable about the importance of
quality in research. EQIPD expects the Process Owner to be identified at the very first step of imple-
menting the EQIPD Quality System (Table 2; core requirement #1).
In the second step, the Process Owner defines the scope - that is, the research unit (lab, territory,
organization or part thereof) where the EQIPD Quality System will be applied - and identifies col-
leagues who will be actively involved in working on the implementation, as well as those who will be
informed and may need to be trained about the new process (core requirement #2; Table 2). To
that end, the Process Owner sets up a communication plan to support the team’s buy-in and to facil-
itate a two-way information flow, in order to also capture feedback related to performance of the
existing and newly introduced practices.
EQIPD also expects research units to define quality objectives (core requirement #3; Table 2).
Although it may sound formal, this core requirement is indispensable and should be articulated at a
level understandable and meaningful to everyone in the research unit.
Why are quality objectives needed? Once the Process Owner has decided to accept the role and
responsibilities and has defined the research unit where the EQIPD Quality System will be imple-
mented, it is worth getting prepared to answer questions that will likely come from colleagues inside
and outside of the research unit: why are we doing this if, at least today, no such quality system is
required by funders or collaboration partners and if, at least on first sight, we can successfully meet
the goals without changing anything?
The answer to these questions helps to justify the efforts and time to be invested in the imple-
mentation and maintenance of the quality system. It also provides an argument by balancing the
potentially negative impact on traditional metrics of scientific success (e.g. fewer positive results
Figure 1. Flexible sequence of implementation of the EQIPD core requirements. Depending on the current needs, a research unit may prioritize the
implementation of one or another core requirement. For example, tasks related to core requirement ‘B’ are highly relevant for the research unit’s
parent institution, the funding organization and a scientific journal where the research team plans to publish the results of their work. In contrast, core
requirement ‘C’ is of lower importance and can, therefore, be addressed at a later timepoint.
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generated, more time needed to complete projects) against the value of higher quality research
(greater confidence in the results and scientific interpretations when results are shared with peers or
published, improved rigor in decision making, more robust publications that stand the test of time,
etc.).
In EQIPD terms, the answer should be documented as a mission statement, that is, a concise sum-
mary of why quality matters for that specific research unit. EQIPD provides examples of how scien-
tists working in different roles and at various types of organizations may answer the question ‘why
quality matters’ (https://eqipd-toolbox.paasp.net/wiki/Why_quality_matters).
It is important that the mission statement is understood, willingly accepted and followed by all
members of the research unit.
If a Process Owner, alone or together with the research team members, cannot generate a clear
and convincing answer to this question, no further steps should be taken and the implementation of
the quality system is best postponed until a good answer is found and the research team is willing to
embrace a quality mindset.
EQIPD Quality System as part of the overall organizational quality
culture
The Process Owner may also be asked and should be prepared to explain that the EQIPD Quality
System does not replace and does not intend to re-interpret any of the existing rules, policies and
other quality systems (which focus on specific areas) that apply to the research unit’s environment.
EQIPD mandates that ‘all activities must comply with relevant legislation and policies’ (core
requirement #4; Table 2) and that a ‘research unit must have a procedure to act upon concerns of
potential misconduct’ (core requirement #5; Table 2). For the vast majority of organizations, no addi-
tional effort will be required to meet these expectations. If so, why are they included in the list of
core requirements?
First, EQIPD does not want to be associated with organizations that engage in or tolerate unac-
ceptable ethical practices or legal violations.
Second, the EQIPD Quality System is focused on quality, not legislation. Legislation may differ
from country to country and for different research activities; hence, it is not possible to specify these
individually in the EQIPD Quality System. Furthermore, EQIPD cannot oversee the way an organiza-
tion deals with the legal requirements of, for example, handling hazardous substances, but empha-
sizes the need for compliance with such regulations as a basis on which all other quality measures
rest.
A particularly relevant example concerns the care and use of laboratory animals that play a pivotal
role in the research process. Society has granted the biomedical research community with the privi-
lege to use laboratory animals in research under very specific conditions, all aiming to prevent inap-
propriate use of these ethically highly sensitive resources. Clearly, it is not acceptable to waste
animals due to poor study design, conduct or analysis.
Ethical concerns on the use of animals in research have promoted the creation of a legal frame-
work in almost every country (e.g. Animal Welfare Act in the US; Directive 2010/63 in the EU). Scien-
tific evidence demonstrates that many aspects of animal care and use that are beyond the legal
requirements have a direct impact on research results (Guillén and Steckler, 2020). The EQIPD
team has developed a concise checklist that allows scientists to review if their animal care and use
processes meet at least a minimum standard that supports the implementation and maintenance of
the EQIPD Quality System. This review could optionally serve as the basis for further, more specific
accreditation of the animal care and use program (i.e. AAALAC International accreditation) to ensure
the implementation of high standards of animal care and use that would further contribute to
increasing the quality of research (Appendix 2 Animal care and use checklist).
EQIPD-defined principles, user-defined content
Implementation of the EQIPD Quality System does not require researchers to stop or reduce ongo-
ing experimental work. It is designed so that it takes only minimal effort to sign up and begin the
journey toward a quality system that should help researchers gradually improve certain quality
aspects of their work.
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The EQIPD Quality System gives guidance on expectations for quality-related measures, defines
criteria for adequate processes (i.e. performance standards; see Appendix 1 Glossary for definition)
and provides examples of how such measures can be developed and implemented. However, it
does not prescribe any pre-determined solutions. Rather, users define their own specific solutions
tailored to their individual settings.
For example, integrity of research data is one of the central concepts that the EQIPD Quality Sys-
tem aims to support. Four core requirements define the desired outcomes for raw data generation
and handling (core requirement #6; Table 2), data storage (core requirement #7; Table 2), data
traceability (core requirement #8; Table 2), and transparency of reported data (core requirement #9;
Table 2). Thus, the ‘what’ is clearly described. However, there are various ways to fulfil these require-
ments. For instance, secure data storage could be achieved by using conventional paper-based labo-
ratory notebooks, electronic laboratory notebooks, custom-built electronic solutions or paper-based
controlled-access archives. Thus, there is flexibility in how integrity of research data could be
achieved, and it is for the users of the system to decide on the best solution for their specific
situation.
Focused on the generation of fit-for-purpose research data
In general, EQIPD recommends that scientists apply protection against risks of bias for every study
and unambiguously disclose the protective measures used. Each study has a particular purpose and
the rigor applied to the study should be defined, documented in advance and be commensurate
with the purpose of the study.
There are modes of research that can tolerate a certain level of uncertainty and do not lead to a
formal knowledge claim (see Appendix 1 Glossary for definition). Such work is an essential part of
the research process and may be used to generate hypotheses or to provide evidence to give the
investigator greater confidence that an emerging hypothesis is valid, to develop new methods or to
‘screen’ compounds for potential effects prior to more formal testing.
There are also modes of research where researchers cannot accept inadequate control of the risks
that can bias the research results (Dirnagl, 2016; Hooijmans et al., 2014). For research that is con-
ducted with the prior intention of informing a knowledge claim, EQIPD requires that maximal possi-
ble rigor is applied (and exceptions explained and documented in the study plan; see Table 4). Such
research will usually (but not always) involve some form of null hypothesis statistical testing or formal
Bayesian analysis. Here, hypotheses are articulated in advance of data collection, with pre-specified
criteria defining the primary outcome measure and the statistical test to be used.
Examples of research requiring maximal possible rigor include:
Table 4. Expectations toward rigor in study design.
All research
Research informing a formal knowledge claim
(i.e. research requiring maximal rigor)
Study plan Should be defined and documented
before starting the experiments
Must be defined and documented before starting the experiments
Study hypothesis Advised to define Must be pre-specified
Blinding Advised to implement Should be implemented, exceptions must be justified and documented
Randomization Advised to implement Should be implemented, exceptions must be justified and documented
Sample size
calculation
Advised to define and document before
starting the experiments
Must be defined and documented before starting the experiments (e.g. included in the
study plan)
Data analysis Advised to define and document before
starting the experiments
Must be defined and documented before starting the experiments (e.g. as a formal
statistical analysis plan and/or included in the study plan)
Inclusion and
exclusion criteria
Advised to define and document before
starting the experiments




Advised to document Must be documented
Preregistration - Should be implemented
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. Experimental studies to scrutinize preclinical findings through replication of results
(Kimmelman et al., 2014);
. Research aimed at generating evidence that enables decisions which will invoke substantial
future investment (e.g. a decision to initiate a new drug development project or to initiate GLP
safety assessment of a new drug candidate);
. Studies for which any outcome would be considered diagnostic evidence about a claim from
prior research (Nosek and Errington, 2020);
. Labor-, resource-, and/or time-intensive studies that cannot be easily repeated.
EQIPD requires that investigators assert in advance whether a study will be conducted to inform
a formal knowledge claim (core requirement #10; Table 2), and that they explicitly state this in the
study (experimental) plans prepared before studies and experiments are conducted.
Further, it is required for all types of research that everyone in the research unit is adequately
trained and competent (core requirement #11; Table 2), has access to protocols for experimental
methods (core requirement #12; Table 2), follows adequate procedures for the handling and storage
of samples and materials (core requirement #13; Table 2), and uses research equipment and tools
that are suitable for the intended use (core requirement #14; Table 2).
A system, not just a collection of guidelines and recommendations
Development and implementation of flexible and fit-for-purpose solutions are usually enabled by
introducing a continuous improvement process (Deming, 1986). Within the EQIPD environment, the
improvement cycle is rooted in the following workflow:
. Understand the rationale for introducing something new or modifying the current work routine
(Why - the Need);
. Understand what is needed to achieve it (What - the Challenge);
. Propose a solution for achieving it (How - fit-for-purpose Solution);
. Evaluate the success of the implementation (Assessment).
As an example, a research organization is seeking a collaboration with a biopharmaceutical com-
pany (Why). The company informs the research organization about its expectations regarding the
raw data record generation, handling, and storage. The research organization recognizes challenges
associated with the storage of raw data as defined by the company (What). The EQIPD Toolbox pro-
vides information on what is the raw data and what are the best practices in recording and handling
the raw data (How). In many cases, the new workflow is applied and has the desired effect. In some
cases, there may be deficiencies identified that require remediation such as changes in the proto-
cols, additional communication, educational and training efforts. Evaluation of the success in imple-
mentation of new processes concludes the cycle (Assessment).
In addition, the successful use of a new method or procedure often requires training, adequate
and timely communication, feedback on incidents and errors, etc. To fully establish the EQIPD Qual-
ity System, several corrective or feedback mechanisms have to be included. These mechanisms iden-
tify factors affecting the generation, processing and reporting of research data before a study is
done (core requirement #15; Table 2; see also Box 1), to analyze and manage the incidents and
errors that may occur during the study (core requirement #16; Table 2), and to monitor the perfor-
mance of the EQIPD Quality System (core requirement #17; Table 2; see also Box 2).
Defining the user of the EQIPD Quality System
The ultimate mission of the EQIPD Quality System is to serve the entire community of scientists con-
ducting non-regulated preclinical biomedical research. To achieve this goal, EQIPD’s dissemination
strategy initially focusses on early adopters, that is, research groups and scientists who:
1. See the value of higher standards of rigor in research to achieve more robust and reliable
results, are willing to learn about and adopt a quality mindset and are prepared to invest effort
to set up the EQIPD Quality System;
2. Consider their standards of rigor are already good, but strive to improve them further, and
would like to establish the EQIPD Quality System as an independent seal of quality;
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3. Can use the EQIPD Quality System to strengthen a grant application, to support decision-mak-
ing in drug discovery and/or to promote their services (e.g. CROs or academic labs active in
the contract research domain) and bolster their reputation;
4. Are motivated by their funders, publishers and collaboration partners to secure high-rigor
research standards (e.g. as a condition for funding or collaboration).
Such early adopters are known to be of critical value in every field where a cultural change is
under discussion. For instance, academic initiatives have successfully addressed research data man-
agement and sharing of best practices by introducing Data Champions that serve as local advocates
Box 1. Managing risks to data quality .
Even under the best circumstances, not all recommended practices and protection measures can be applied to a working envi-
ronment or research study, leaving a potential risk of failure. The EQIPD Quality System recognizes the following main areas
where risk assessment should be conducted with risks made transparent and, if appropriate, documented:
1. Alterations from strongly recommended practices (i.e. situations in which the language of the EQIPD guidance includes
’should’ and the research unit justifies why it does not or cannot apply). These assessments are done at regular intervals
by the Process Owner;
2. Key and support processes that are inherently associated with risks endangering the validity of the results (e.g. risk of
unblinding; emergency access to blinding codes). These assessments are done by scientists responsible for a study plan;
3. Changes in the environment inside of the research unit (changes in personnel; facility changes, etc.). These assessments
are done or initiated ad hoc by the Process Owner.
4. Changes in the environment outside of the research unit (changes in personnel; facility changes, etc.). These assessments
are done or initiated ad hoc by the Process Owner.
Box 1—figure 1. Areas of risk assessment.
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for good data practices (e.g. https://www.data.cam.ac.uk/intro-data-champions). Peer-to-peer learn-
ing eventually supports the dissemination of good practices beyond the early adopters.
The early adopters of the EQIPD Quality System, through their feedback to the EQIPD consor-
tium, will help optimize the balance between the benefits of implementing such a system and any
potential adverse consequences (e.g. resources allocated, reduction in conventional indices of scien-
tific productivity). A positive balance will support further dissemination of the EQIPD Quality System
Box 2. Self-assessment.
The primary objectives of the self-assessment are to confirm that the research unit has everything in place for proper perfor-
mance of the fit-for-purpose EQIPD Quality System, and to set the basis for internal or external quality checks/accreditation
mechanism.
The Process Owner is responsible for defining the scope and frequency of this self-assessment, which is expected to involve all
members of the research unit to ensure that all quality goals in the research unit have been considered and achieved.
As part of the self-assessment, there are spot checks conducted on selected documents (core requirements ## 11, 12, 16, 17;
Table 2) and laboratory activities (core requirements ## 6, 7, 8, 9, 10, 13, 14, 15; Table 2). The Process Owner completes a
paperless assessment of several solutions being up-to-date (core requirements ## 1, 2, 4, 5; Table 2), reviews and, if necessary,
updates documentation (core requirements ## 2, 3, 6, 7, 8; Table 2), and engages the team in the discussion and review of cer-
tain processes (core requirements ## 3, 5, 13, 16; Table 2). The self-assessment itself is a core requirement (#17; Table 2) and
can be conducted using a template provided in the Toolbox.
Box 2—figure 1. Types of self-assessment activities.
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and help broader research communities take advantage of the work done by the EQIPD team and
the early adopters.
It is a general understanding that not all research units are equally prepared or willing to imple-
ment a Quality System, an effort that requires investing time and resources. Tools developed and
shared by EQIPD can also be used for other purposes – for example, as a source of information
about specific aspects of good research practice, as a guidance for specific types of projects (e.g.
industry-academia collaboration), or to enable a specific collaboration project by providing a pur-
pose-fit certification of the current practices being in line with the EQIPD expectations (Table 5).
Since the scientists themselves will be the main users of the EQIPD framework, their leading and
proactive role in improving the quality of their own scientific data will define the ways the framework
can be used to prepare more and more research units to accept a Quality System as a means for
long-term maintenance or research rigor standards.
Implementation of the EQIPD Quality System
Even a lean and user-friendly quality system requires effort and resources to be implemented and
maintained. This consideration makes it important to emphasize that a decision to start implement-
ing the EQIPD Quality System should be well justified and regularly checked by the Process Owner
and discussed with the research team.
Size of the research unit
The EQIPD Quality System can be implemented at any level (university, research institute, company,
or a laboratory). While this is the desired case, EQIPD encourages the transition toward better qual-
ity practices at the level of individual labs, departments or research groups, no matter how small
they are, provided that there is a researcher capable, authorized and willing to take on the role of
Process Owner.
The EQIPD Quality System is not intended to be used at the level of individual projects. Other-
wise, it may create confusion and increase the risk of errors as the same people within a research
unit may follow separate research quality practices depending on the project that they are working
on.
Table 5. Levels of use of the EQIPD framework.
Levels of use: Information only (incl. training) Purpose-fit certification Quality System
EQIPD guidance: Recommendations on best practices,
examples, templates
Basic set of core requirements Full set of core requirements
Main users: Research units, funding organizations Research units Research units
Expected use: As necessary, follow specific
recommendations or use provided tools
to improve work processes (e.g. increase
transparency or make raw data findable
or improve reporting)
As appropriate, use information
provided by EQIPD in training programs;
communicate to collaborators, grantees,
etc.
Confirm that current quality practices
are in line with the basic set of EQIPD
core requirements (related to data
integrity and rigor in study design,
conduct, analysis, and reporting)
Align current research quality practices
with the EQIPD expectations (implement
full set of core requirements including
those that define quality system – i.e.
availability of resources, process owner,
quality objectives, and continuous
improvement mechanisms)
Dedicated efforts by the




(proportional to quality objectives)
Context of use: Research unit is informed about
expectations by current or future
collaborators, funders, sponsors,
publishers, etc.
Flexible solution driven by the time- and
resource-critical needs of specific
collaboration(s)
Stable solution for long-term
maintenance of research rigor standards
Assessment by the EQIPD
team:
No Yes Yes
Bespalov, Bernard, Gilis, et al. eLife 2021;10:e63294. DOI: https://doi.org/10.7554/eLife.63294 13 of 26
Tools and resources Neuroscience
Implementation path
There are several ways in which the EQIPD core requirements can be introduced within a research
unit in terms of timing and sequence (Figure 2). Whether supported by the (optional) EQIPD tools
or not, any of the possible implementation scenarios are acceptable as long as the outcome is the
same, that is, a quality system implementing all 18 core requirements.
The implementation path suggested by EQIPD envisions three phases (Appendix 3 Implementa-
tion path):
Phase 1– A short list of cornerstone actions that are the same for all research units to help users
understand why things are done, as well as ensuring that efforts triggered by the EQIPD framework
have immediate impact (e.g. best practices to support data integrity and traceability).
Phase 2 – Users develop solutions for challenges directly connected to their environment or
needs communicated by their funders, publishers and collaboration partners. During this phase,
users meet most of the EQIPD core requirements while developing a habit of working toward a qual-
ity system.
Phase 3 – Completion of the remaining core requirements enabling formal recognition of a func-
tional quality system.
The implementation is concluded with an important sustainability checkpoint: the Process Owner
is expected to estimate the required resources and make them available for maintaining the EQIPD
Quality System (core requirement #18; Table 2).
Supporting tools
EQIPD has developed several tools (Figure 2) that are freely available to support the implementa-
tion and maintenance of the Quality System:
1. The Toolbox is a structured collection of information that enables users to build or select solu-
tions for customized research needs. This Toolbox is built using wiki principles. The Toolbox
contains a growing body of information about existing guidelines, recommendations, exam-
ples, templates, links to other resources, literature references, or just guidance on how to
address a specific topic and will be regularly updated.
Figure 2. Implementation of the EQIPD Quality System (QS): From Core Requirements (CR) to assessment of a fully functional system. The 18 CRs are
the expectations formulated by EQIPD that serve as the starting point for implementing the QS. At any step during the implementation, the use of
EQIPD tools is voluntary and serves only the purpose of making the implementation and maintenance of the QS easier. As the first step, unless such
information is available from other sources, the research unit may consult with the Toolbox to obtain relevant research quality-related information. Once
the necessary information is obtained, the research unit applies this knowledge and monitors the progress. This can be done using the Planning Tool,
using alternative project management resources or even without any such tools. The Dossier is a repository of documents and information that are
specific to the user’s research unit and that is organized according to a structure suggested by EQIPD (to keep all research quality-related information
in one place and make it easily findable). However, the research unit may also opt to use its own way to store information. Finally, once the
implementation is completed, the research unit may initiate an assessment to get feedback from experts outside of the research unit (either quality
professionals within the same organization or a third party).
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2. The Planning Tool is a user interface, designed to review the needs of researchers and is spe-
cific to their environment and focus of their research. Summarized expectations of funders,
publishers, and collaboration partners can be entered in the Planning Tool either directly or
using a special template called the Creator Tool.
3. The Dossier is a structured collection of customized documents and information related to
research quality in a given research unit.
EQIPD does not intend to insist that researchers use these tools and rather sees their application
as optional.
The EQIPD Quality System: compliance mechanisms
The EQIPD system is a voluntary quality framework that enables research units to fulfill their own
quality needs, for example, community guidelines or funder requirements.
Traditional quality systems require either internal (within the organization) or external auditors to
check compliance with its system. This in turn requires that organizations employ dedicated and ade-
quately trained quality professionals that understand the specific language in these quality regula-
tions and ensure that the documentation formats correspond to the norm and nomenclature of the
certifying organization.
The EQIPD Quality System is conceived as beginning with research scientists and extending to
the research environment, and the compliance mechanisms are in line with this approach typically
requiring no quality professionals.
Self-assessment
The Process Owner is expected to use a self-assessment form provided by EQIPD to check whether
Core Requirements and research unit-specific needs are appropriately addressed. The form guides
the Process Owner through each core requirement, links out to the corresponding online Toolbox
item, which describes background, expectations and provides further guidance documents.
The self-assessment serves two purposes. On the one hand, it allows the Process Owner to moni-
tor performance of the quality system. On the other hand, it provides the base for an external
assessment.
External assessment
The external assessment of the research unit, performed as peer review, is a quality verification step
that is recommended and important for the full implementation and the successful maintainance of
QS. However, this step is not required and adopters of the Quality System may stop at the self-
assessment stage.
External assessors review the self-assessment document and may request the research unit to
provide additional documents. Assessors decide, based on the information provided, whether each
core requirement is sufficiently addressed or whether additional verification is needed during the
assessment interview.
The results of this preliminary assessment and further questions are shared with the research unit
and are discussed in detail and clarified during the subsequent interview. A report is prepared by
the assessors that details the results of the assessment, contains suggestions for improvement and
ultimately confirms whether the research unit is compliant with all core requirements. Research units
that successfully implemented the EQIPD Quality System receive a certificate of EQIPD compliance.
Several research units have completed the implementation of the EQIPD Quality System and
have been evaluated by the EQIPD team.
External assessment is currently performed by scientists that developed the EQIPD Quality Sys-
tem. A training module for future assessors will be released to ensure the reliability and consistency
of assessments conducted by different experts.
Moreover, anticipating a large demand for external assessments, the EQIPD team evaluates and
compares the reliability of hybrid external assessment models combining onsite visits and remote
interviews.
Importantly, EQIPD aims to make the assessment process as straightforward as possible. EQIPD’s
expectations are concisely summarized for each core requirement in a document that is regularly
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updated and available via the Toolbox. Further, the EQIPD team advises to refer to the five key prin-
ciples (Table 3) whenever a specific answer is not yet provided in the EQIPD guidance.
Last but not least, EQIPD’s vision is that the Quality System serves the research units in the role
of a partner, stimulating and guiding the continuous improvement in research rigor. With that in
mind, EQIPD places a lot of weight on the competence and engagement of Process Owners con-
ducting regular spot checks of key research processes and documentation.
Enhancing Quality in Preclinical Data (EQIPD): the outlook
On September 30, 2020, the EQIPD Quality System was released for broad deployment and unre-
stricted use by the research community.
To enable the maintenance and further development of the EQIPD framework beyond the IMI
project phase, the EQIPD team is implementing a governance model (Figure 3). The proposed
model comprises three closely interacting levels:
. A strategic level represented by the EQIPD Guarantors, a group of the EQIPD project team
members responsible for the overall guidance, administration of academic and educational
programs, and the dissemination of the EQIPD vision. The EQIPD Guarantors will be sup-
ported by an Ethics and Advisory Board, a consultative body composed of current EQIPD con-
sortium members, associate collaborators and advisors as well as key opinion leaders in the
field of good research practice.
Figure 3. The proposed future governance model of EQIPD. The EQIPD Guarantors group and the EQIPD Ethics and Advisory Board are responsible
for the overall guidance, administration of academic and educational programs, as well as dissemination of the EQIPD vision (Strategic level). An
independent partner organization, commissioned by the EQIPD Guarantors, will provide the operational support and the day-to-day services for the
EQIPD community (Operational level). The EQIPD Stakeholder group, composed of scientists, funders, quality professionals, manufacturers of research
tools, and publishers, provides feedback on the practical aspects of the EQIPD Quality System and facilitates connections to a broader biomedical
research community (Community level).
Bespalov, Bernard, Gilis, et al. eLife 2021;10:e63294. DOI: https://doi.org/10.7554/eLife.63294 16 of 26
Tools and resources Neuroscience
. An operational level represented by an independent globally acting partner organization,
commissioned by the EQIPD Guarantors to provide the operational support and services
required for day-to-day business management (including technical support and training for the
research units during the implementation and maintenance of the EQIPD Quality System).
. A community level that is represented by the EQIPD Stakeholder group, a diverse group of
scientists, funders, quality professionals, manufacturers of research tools, and publishers that
provide feedback on practical aspects of the EQIPD Quality System and facilitates connections
to a broader biomedical research community.
The next milestones for the EQIPD team are:
. Launch of an educational platform that will support both the use of the EQIPD Quality System
and provide more general training in the field of good research practice;
. Analysis of geographical and cultural differences that may affect the acceptance of the EQIPD
Quality System and that may require adaptations in the associated framework;
. Evaluation of the impact of implementation of the EQIPD Quality System on research quality,
to inform further development of the EQIPD framework;
. The EQIPD Quality System was developed with the focus on the users and their needs. The
EQIPD collaborators will maintain and expand this focus further.
The EQIPD team is actively engaged in discussions with funders (public and private) and publish-
ers to develop instruments and mechanisms that will allow scientists to further benefit from the use
of the EQIPD Quality System.
All scientists engaged in biomedical research are invited to join the growing community of the
EQIPD Quality System users and supporters (http://www.eqipd.online).
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Challenge An unmet requirement that must be appropriately matched by a specific
solution.
Continuous improvement The process ensuring that new risks and challenges are identified and
appropriately met by adapting the existing quality system.
Core requirements Tasks defined by EQIPD for all users/institutions that must be fulfilled to reach
the status of a functional quality system.
Dossier
(EQIPD Dossier)
A structured and categorized collection of various quality-related items (such
as protocols for experimental methods and training records) that are
developed and stored by a research unit as solutions to challenges specific to
their needs.
Framework (EQIPD Framework) The concept, implementation strategy, software and tools developed by
EQIPD that direct and support the users in building the fit-for-purpose EQIPD
Quality System.
Key process An action or series of actions that directly impact the experimental generation
of research products, data and their quality.
Knowledge claim A formal knowledge claim can be thought of as a statement that a research
project or study has established new knowledge, or consolidated existing
knowledge, with sufficient certainty that that knowledge can now be acted
upon. The required level of certainty might depend on the nature (risk and
potential benefits) of the possible action. For instance, the required level of
confidence in the efficacy of a molecule will be different for a decision to
proceed to a clinical trial compared to deciding to publish the results of a
study or to initiate a lead identification campaign for a newly validated target.
Needs Reasons to introduce and maintain high quality derived from a research unit’s
mission and research objectives that can be dictated by stakeholders (e.g.,
funders) or defined by EQIPD. They are identified by the research unit.
Must Indicates actions that EQIPD considers as imperative and mandatory or as a
requirement.
Performance standards Performance standards define the desired outcome in detail and provide
measurable criteria for assessing whether the outcome is achieved, but do not
specify a method or technique for achieving the desired outcome
Planning tool (EQIPD Planning tool) A software tool supporting the research unit in order to implement the EQIPD
Quality System in a given institution.
Process owner A person within the organization/research unit who has the necessary
resources or access to them, the competence and the authority to implement
and maintain the EQIPD Quality System.
Regulated research, or research
subject to regulation
Research activities for which national (e.g., FDA) or international (e.g., EMA,
OECD) governmental bodies and agencies have specific responsibility for
regulating the research activity as well as setting expectations and
inspections.
Regulated research is typically subject to compliance with the formally defined
good practices such as Good Laboratory Practice, Good Manufacturing
Practice, Good Clinical Practice, Good Pharmacovigilance Practice, etc.
Robust A data set is said to be robust if it is not sensitive to departures from the
assumptions on which its validity is strictly predicted (e.g., that the study plans
used to generate data are protected against risks of bias).
Should A strong recommendation; however, EQIPD recognizes that individual
circumstances might justify an alternative strategy.
Solution An answer to an identified challenge.
Support process An action or series of actions that provide the means needed to execute key
processes in a quality-oriented manner.
Toolbox
(EQIPD Toolbox)
A structured and categorized online collection of various quality-related
information, such as guidelines, protocols, and tools.
Bespalov, Bernard, Gilis, et al. eLife 2021;10:e63294. DOI: https://doi.org/10.7554/eLife.63294 21 of 26
Tools and resources Neuroscience
Appendix 2
Animal care and use checklist
This checklist is intended for research units conducting studies using laboratory animals and not hav-
ing a full accreditation from AAALAC (or equivalent). Guided by this checklist, research units are
expected to develop a description of the animal care and use program.
1. Ethical evaluation and authorization process of animal use. The participation of the following
bodies must be described:
 Institutional body(ies) involved
 External body(ies) involved
 Competent Authority
2. Animal procurement and identification. The following topics must be defined and
documented:
 Source of animals
 Transportation
 Acclimation and quarantine procedure/periods
 Acceptance criteria
 Identification method
3. Animal housing conditions. The following topics must be defined and documented:
 Description of caging/enclosure (dimensions, open, IVC, flooring, etc.)
 Animal numbers by type of caging/enclosure
 Environmental enrichment
 Justified cases for single housing of social species relating to experimental procedures
(e.g., metabolic caging, post-surgery), veterinary intervention or social incompatibility
4. Animal environmental conditions. The following topics must be controlled and recorded:
 Air changes/hour in room and IVC
 Air temperature ranges by species
 Possibilities for thermoregulation at cage level
 Ranges of relative humidity by species
 Light source, intensity and cycle
5. Food, watering and bedding. The following topics must be defined and documented:
 Feed source, type and treatment (e.g., autoclave, irradiation, etc)
 Feed storage conditions
 Feed/water provision (e.g., ad libitum, restricted)
 Water source and treatment (e.g., acidification, chlorination, autoclave)
 Water provision method (e.g., bottles, automatic) and frequency of change (in case of
bottles)
 Type of bedding and treatment (e.g., autoclave, irradiation)
 Frequency of bedding change, and relation with experimental procedures if any
6. Sanitation procedure. The following topics must be defined and documented:
 Frequency of change of microenvironment items: cage, lid, water bottle, etc.
 Frequency of sanitation of macroenvironment: room level
 Agents used
 Monitoring effectiveness of sanitation of caging/enclosures
7. Frequency and procedure of observation of animals. The following topics must be defined
and documented:
 Personnel involved (animal care and/or research teams)
 Reporting method to veterinarian and/or investigators
 Implementation of defined humane endpoints
 Response in case of unexpected outcomes
8. Animal health and genetic monitoring. The following topics must be defined and
documented:
 Health monitoring program and reports for the research colony
 Scientific nomenclature of the species, with special emphasis on genetically modified
animals
 Method of control of genetic drift, if applicable
9. Veterinary interventions during the study. The following topics must be recorded:
 Veterinary interventions and drugs used (e.g., analgesics, antibiotics, etc)
10. Surgical procedures. The following topics must be defined and documented:
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 Drugs used for surgical procedures
 Aseptic technique
 Dedicated room and equipment
 Recovery procedures and post-surgical monitoring
11. Animal euthanasia procedures. The following topics must be defined and documented:
 Euthanasia methods: default method and others according to type of experiment and
species
 Euthanasia conditions: separation from other animals, dedicated area
 Methods of confirmation of death
Bespalov, Bernard, Gilis, et al. eLife 2021;10:e63294. DOI: https://doi.org/10.7554/eLife.63294 23 of 26
Tools and resources Neuroscience
Appendix 3
The EQIPD Quality System implementation path (optional)
Phase 1: Same for everyone
The first task is to establish a basis for building a quality system. This basis includes absolute must-
have (core) elements that:
. are the same for all labs
. are required to support the next steps
. can be completed within days
This set of requirements was chosen according to the principles that are uniform to all types of
research units and is completed by the following four steps:
Step 1. Establish a Process Owner
. WHY: This process needs a leader who takes the overall responsibility for implementing the
EQIPD Quality System and is willing to drive the process forward.
. WHAT: EQIPD defines the Process Owner as a person within the research unit who has the
necessary resources or access to them, the authority, the competence and takes the respon-
sibility to start all implementation steps needed to establish the EQIPD Quality System.
. HOW: Different research units may have differing criteria for identifying such leaders, ranging
from a self-nomination for a small research unit to dedicated professionals in larger
organizations.
Step 2. Define quality objectives
. WHY: The EQIPD Quality System will turn into a burden and resources will be wasted if the
Process Owner and the research team do not understand the objectives of investing time
and efforts into the implementation and maintenance of the system.
. WHAT: The Process Owner, alone or in discussions with the research team, develops a con-
cise summary of why quality matters for that specific research unit. The Process Owner dis-
cusses with the team what specifically is at stake if the proper quality is not maintained.
. HOW: EQIPD provides a template with guiding questions to develop a quality objective sum-
mary (called ‘Mission’) as well as examples of statements on how a quality system or higher
research rigor could help scientists achieve goals in different environments and at different
positions.
Step 3. Set up a communication plan in the research unit where the EQIPD Quality System is to
be applied
. WHY: The EQIPD Quality System can only be implemented in a specific research environment
where roles and responsibilities of every team member are clearly defined and there is a clear
plan for communication between team members.
. WHAT: Define a research unit (lab, territory, organization or part thereof) where the EQIPD
Quality System will be applied in order to identify all colleagues who need to be informed
about the new process, colleagues who need to be actively involved in working on the
EQIPD Quality System implementation; set up a communication plan/schedule of working
meetings; make sure that the communication plan supports a two-way information flow (i.e.,
also to capture feedback related to the performance of the existing and newly introduced
practices).
. HOW: Depending on the organization, the initial information can be distributed via email,
the intranet or during regular or extraordinary team meetings. The Process Owner may
assemble a dedicated team or appoint a colleague to be responsible for implementing the
EQIPD Quality System. The Process Owner is responsible for establishing a Communication
Plan. EQIPD provides guidance for establishing the communication plan and templates for
documenting all roles and responsibilities. All these templates (as well as all other guiding
and supporting information) can be found in the Toolbox.
Step 4. Establish a documentation plan to make data and associated documents traceable and
any changes transparent
. WHY: Traceable and transparent handling of all information related to study design, conduct,
analysis and reporting is a pre-requisite for good research practice.
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. WHAT: The documentation plan should ensure the ability to find the source of data (raw and
analyzed) that is presented in a report or presentation and should contain a contemporane-
ous description of the experiment from which the data originated. A qualified reviewer
should be able to link figures, graphs, conclusions, and other summary data to the raw data
that was processed/analyzed; link the summary data to the corresponding experiment
described in a lab notebook entry; and, likewise, link the lab notebook entry to the raw data
(e.g., when generated by an automated instrument).
. HOW: Depending on the organization, resources and workflows, this could be an electronic
or paper-based lab notebook, a more complex Laboratory Information Management System
(LIMS), or some other form of archiving as long as the information handling procedures are
transparent and properly documented.
Phase 2 – Defined by user-specific needs
During this Phase, the primary focus is on challenges that are specific to the research unit where the
EQIPD Quality System is being established.
The team led by the Process Owner identifies needs pertinent to the researchers’ environment –
e.g., related to funding sources, collaboration partners, reporting and publication strategies, institu-
tional, national and applicable international laws and regulations, use of animal subjects, etc.
Some of these needs have already been reviewed by the EQIPD team, summaries are available
from the Toolbox.
Others will need to be reviewed by the Process Owner and the team to identify and develop
appropriate solutions.
There are no time limits set to complete this phase. The organization may also remain in this posi-
tion if, for example, there are not enough financial or personnel resources to continue the process.
The decision to move to the next phase is made by the Process Owner and the team based on the
following criteria:
. All high-priority challenges have been addressed;
. There are motivation, resources and organizational support to complete the implementation
of the EQIPD Quality System.
Phase 3 – Complete the system
The EQIPD team has designed a set of 18 Core Requirements (Table 2) that must be fulfilled in
order to reach the status of a functional quality system. Several of these Core Requirements are
addressed during Phase one and Phase 2.
The goal of Phase three is to address those Core Requirements that have not been implemented
so far but are essential to complete the development of the EQIPD Quality System.
However, for different research units, the remaining effort will be different because the Core
Requirements addressed during Phase two are selected/chosen depending on the user-specific
needs.
Therefore, it is anticipated that there will be research units for which Phase three requirements
will only be a small step, as most Core Requirements have already been implemented during Phase
1 and 2, and those for which this final step may be a significant task demanding time and resources.
EQIPD also explicitly acknowledges the possibility for research units to not pursue the completion
of the System. In fact, going through Phase 1 and 2 in many cases may already enable high quality
research outputs and researchers may be satisfied with the progress achieved and make an indefi-
nite pause.
*****
In summary, the core requirements necessary to build and declare a functional EQIPD Quality Sys-
tem are spread over three implementation phases. It is expected that, in most cases, these require-
ments will not appear as a burden because:
. during Phase 1, the number of requirements is kept to an absolute minimum and the goal is
only to ensure that the research team has everything needed in place to start building a
Quality System;
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. during Phase 2, requirements are mostly introduced indirectly – via research processes that
are important and fully understandable for the users (i.e., while addressing the various needs
specific to their environment, from funding and publishing to environmental health and
safety);
. during Phase 3, research teams deal with the remaining requirements that may be easier to
handle because:
 a major portion of the work has already been done, and
 there is a habit established that makes continuous improvement a manageable routine.
After the Quality System is established, the maintenance focus is on continuous improvement
that accompanies the use of the Quality System. For example, there may be new needs and chal-
lenges identified.
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